Development of a Novel 99m Tc-Labeled Folate Derivative Containing Phenyl Isonitrile to Target Folate Receptor with Reduced Renal Uptake
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Junhong Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (Nationa…. Hauptthemen laut MEDLINE: Folic Acid, Kidney, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
The folate receptor has attracted much attention in the field of radiolabeled imaging agents due to the significant difference in its expression levels between tumor cells and most normal cells. However, the development of folate-based imaging agents has been limited by their high uptake in the kidney. In this study, to reduce the high renal uptake of radiolabeled folate-based tracers, a phenyl-isonitrile folate derivative (CNMBFA) was designed and labeled with technetium-99m. The complex obtained via the one-step kit labeling method had a high labeling yield (>95%) and high in vitro stability and hydrophilicity (log D7.4 = -1.72 ± 0.13). The results of the in vitro cell uptake and blocking studies and competitive binding experiments revealed that the [[99mTc]Tc-(CNMBFA)6]+ complex was specific for the folate receptor. Biodistribution and inhibition studies in KB tumor-bearing mice revealed moderate uptake and significant inhibition of the complex in tumors, whereas the renal uptake of [[99mTc]Tc-(CNMBFA)6]+ was significantly lower than that of previously reported tracers. Micro-SPECT/CT images further supported its ability to target the folate receptor for tumor imaging. Taken together, these results indicate that [[99mTc]Tc-(CNMBFA)6]+ is a potential tumor imaging agent that has good tumor-targeting properties with minimal radiation damage to the kidney.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Norm…
- Department of Nuclear Technology and Application, China Institute of Atomic Energy, Beijing 102413, China.
- Key Laboratory of Beam Technology of the Ministry of Education, School of Physics and Astronomy, Beijing Normal University, Beijing 100875, PR China.
- China Isotope & Radiation Corporation, Beijing 100089, China.
- CAEA Center of Excellence on Nuclear Technology Application for Engineering and Industrialization of Radiopharmaceuticals, Beijing 102413, China.
ORCID-Profile: Qing Ruan, Junbo Zhang
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
Zitieren
APA
Feng, J., Zhang, X., Jiang, Y., Wang, Q., Ruan, Q., Yin, G., Han, P., Du, J., & Zhang, J. (2024). Development of a Novel 99m Tc-Labeled Folate Derivative Containing Phenyl Isonitrile to Target Folate Receptor with Reduced Renal Uptake. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00667
Vancouver
Feng J, Zhang X, Jiang Y, Wang Q, Ruan Q, Yin G, et al. Development of a Novel 99m Tc-Labeled Folate Derivative Containing Phenyl Isonitrile to Target Folate Receptor with Reduced Renal Uptake. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00667
BibTeX
@article{Feng2024,
author = {Feng, Junhong and Zhang, Xuran and Jiang, Yuhao and Wang, Qianna and Ruan, Qing and Yin, Guangxing and Han, Penwen and Du, Jin and Zhang, Junbo},
title = {Development of a Novel 99m Tc-Labeled Folate Derivative Containing Phenyl Isonitrile to Target Folate Receptor with Reduced Renal Uptake},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00667}
}
EUVIMED